Merck Sees Strong Cholesterol Market In ‘04; Zocor Growth, Profit From Zetia

Merck expects Zocor sales to remain in the $5 bil. range in 2004 despite generic erosion overseas and the introduction of new competitors in the cholesterol class

More from Archive

More from Pink Sheet